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Helicobacter pylori is a gastric bacterial pathogen that is etiologically linked to human gastric cancer. The
cytotoxin-associated gene A (CagA) protein ofH. pylori, which is delivered into gastric epithelial cells via bac-
terial type IV secretion, is an oncoprotein that can induce malignant neoplasms in mammals. Upon delivery,
CagA perturbs multiple host signaling pathways by acting as an extrinsic scaffold or hub protein. On one
hand, signals aberrantly raised by CagA are integrated into a direct oncogenic insult, whereas on the other
hand, they engender genetic instability. Despite its decisive role in the development of gastric cancer,
CagA is not required for the maintenance of a neoplastic phenotype in established cancer cells. Therefore,
CagA-conducted gastric carcinogenesis progresses through a hit-and-run mechanism in which pro-onco-
genic actions of CagA are successively taken over by a series of genetic and/or epigenetic alterations
compiled in cancer-predisposing cells during long-standing infection with cagA-positive H. pylori.Introduction
Gastric cancer is the fourth most common malignancy and the
second leading cause of cancer-related deaths, accounting for
10% of total cancer deaths worldwide (Parkin, 2004). The vast
majority of gastric cancers are adenocarcinomas, which are
pathohistologically classified into intestinal and diffuse types.
Gastric cancer is also characterized by large geographical vari-
ations in its incidence and, indeed, more than half of the total
gastric cancers are in East Asian countries such as Japan, South
Korea, and China.
Like other cancers, gastric cancer develops through a multi-
step process, the progression of which is variably influenced
by both host genetic and environmental factors (Correa, 1988;
Shanks and El-Omar, 2009). Among those, the gastric pathogen
Helicobacter pylori is the strongest risk factor, playing virtually
indispensable roles in the development of both intestinal and
diffuse gastric noncardia adenocarcinomas (Peek and Blaser,
2002). The gastric pathogen has coevolved with and adapted
well to human populations and has currently infected more
than half of the entire human population. Given that most mem-
bers of the genus Helicobacter thrive in the intestinal and/or liver
tract of mammals, the ancestor of H. pylori could have been one
of such enterohepatic Helicobacter species that successfully
migrated to the stomach upon the acquisition of urease during
evolution. H. pylori urease converts urea from gastric juices
into bicarbonate and ammonia, thereby neutralizing stomach
acid around H. pylori for its survival. Subsequently, a fraction
of H. pylori strains became more virulent by acquiring the ability
to produce and secrete a protein called cytotoxin-associated
gene A (CagA). CagA is encoded by the cagA gene, one of
30 genes present in a 40 kpDNA segment termed the cag path-
ogenicity island (cag PAI), which is thought to have been intro-
duced into the H. pylori genome via horizontal transfer from an
unknown organism. Many of the cag PAI genes encode compo-
nents of a syringe-like pilus structure known as a type IV secre-
tion system (TFSS) through which CagA is delivered into the
cytoplasm of gastric epithelial cells during bacterial attachment306 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.(Fischer, 2011). The worldwide infection ratio of cagA-positive
versus -negative strain is approximately 6:4, except in East Asian
countries, where almost all of the isolated H. pylori strains are
cagA-positive. Infection with cagA-positive strains increases
the risk of gastric cancer by at least one order of magnitude
more than that infection with cagA-negative strains (Ekstro¨m
et al., 2001). Considering technical problems in detecting cagA
or CagA in earlier studies, it is highly likely that the cagA-positive
strain, and not the cagA-negative strain, is the H. pylori that
directs gastric carcinogenesis. This notion is experimentally sup-
ported by the infection of Mongolian gerbils with H. pylori
demonstrating that intact cag PAI robustly facilitates bacterial
colonization in the stomach body, resulting in corpus-predomi-
nant atrophic gastritis, a precancerous condition (Rieder et al.,
2005). The oncogenic potential of CagA was directly demon-
strated by the observation that transgenic mice systemically
expressing cagA spontaneously developed gastrointestinal car-
cinomas and hematopoietic malignancies (Ohnishi et al., 2008).
In a Zebrafish model, transgenic expression of CagA enhanced
intestinal carcinogenesis caused by a mutation in the tumor-
suppressor gene p53 (Neal et al., 2013), providing additional
in vivo evidence for the oncogenic capacity of CagA. Although
the contribution of other H. pylori proteins to disease develop-
ment, such as vacuolating cytotoxin A (VacA) and outer inflam-
matory protein A (OipA), has also been shown (Yamaoka,
2010), accumulating evidence clearly points to a central role of
CagA in gastric carcinogenesis.
CagA as a Bacterium-Derived Scaffold or Hub Protein
CagA is a 120–145 KDa H. pylori protein that shows no signifi-
cant homology with known proteins. The size variation is due to
structural diversity in its C-terminal region (Hatakeyama, 2004).
CagA is the only known protein substrate of the H. pylori TFSS.
Upon delivery into gastric epithelial cells, CagA is localized to
the inner leaflet of the plasma membrane, where it undergoes
tyrosine phosphorylation. Initialmechanistic insight into the path-
ogenic action of CagA was provided upon the discovery that
Figure 1. Structural Diversity of H. pylori
CagA
(A and B) East Asian CagA (A) and Western CagA
(B) are respectively characterized by the presence
of an EPIYA-D segment and an EPIYA-C segment,
to which SHP2 binds in a tyrosine-phosphory-
lation-dependent manner. In Western CagA spe-
cies, the EPIYA-C segment duplicates with a
variable number, usually one to three times, in
tandem. The EPIYA-A and EPIYA-B segments
serve as sites for Csk binding upon tyrosine
phosphorylation. The CM motif interacts with
PAR1. In general, Western CagA contains a single
Western CM motif, whereas East Asian CagA
possesses at least two Western CM motifs.
(C) There are a few CagA variants containing
atypical combinations of Western and East Asian
CM motifs.
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domain-containing protein tyrosine phosphatase (SHP2) in a
tyrosine-phosphorylation-dependent manner (Higashi et al.,
2002). The finding draws an analogy between CagA and the
mammalian Gab family of scaffold proteins, which also form a
complex with SHP2 in a tyrosine phosphorylation-dependent
manner beneath the plasma membrane. This parallel gives rise
to the possibility that, despite a lack of sequence homology, the
bacterial protein behaves as a pathogenic scaffold or hub in
mammalian cells (Hatakeyama, 2003). The idea that CagA is a
Gab mimic is appealing and supported by Drosophila genetics
demonstrating that CagA can rescue a deficiency in Drosophila
Gab (DOS). Moreover, the CagA-mediated rescue of DOS defi-
ciency requires Drosophila SHP2 (Corkscrew), providing addi-
tional evidence for the genetic interaction between CagA and
SHP2 (Botham et al., 2008). CagA has been reported to interact
with a variety of human proteins in both phosphorylation-depen-
dent and -independent manners (Hatakeyama, 2011). Although
many of those interactors require additional confirmational
studies, it is certain that CagA acts as a promiscuous scaffold
or hubprotein that simultaneouslydisturbsmultiple host proteins.
EPIYA-Dependent CagA-Host Protein Interactions
The CagA C-terminal region is noted for the presence of a vari-
able number of Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs, which serve
as tyrosine phosphorylation sites. With respect to the amino
acid sequence surrounding each of the EPIYA motifs, four
distinct EPIYA segments (termed EPIYA-A–EPIYA-D) have
been classified (Hatakeyama, 2004, 2011).H. pylori strains circu-
lating in East Asian countries carry East Asian CagA, which
contains EPIYA-A, EPIYA-B, and EPIYA-D segments, whereas
H. pylori strains in the rest of the world carry Western CagA,
which contains EPIYA-A, EPIYA-B, and multiple EPIYA-C seg-
ments (usually repeated one to three times in tandem) (Figure 1).
When delivered into host cells, CagA undergoes tyrosine phos-
phorylation on these EPIYA segments initially by Src family
kinases (SFKs) and then c-Abl kinase. A recent study showedCell Host & Microbe 1that SFKs specifically phosphorylate the
EPIYA-C or EPIYA-D segments, whereas
c-Abl phosphorylates all four EPIYA seg-
ments without overt specificity (Mueller
et al., 2012). A critical role for EPIYAphosphorylation in in vivo tumorigenesis has been indicated by
the observation that, in contrast to transgenic mice expressing
wild-type CagA, transgenic mice expressing a phosphoryla-
tion-resistant CagA failed to induce neoplasms (Ohnishi et al.,
2008).
Upon tyrosine phosphorylation, the EPIYA-C or EPIYA-D
segment acquires the ability to bind to one of the two mutually
related SH2 domains of SHP2. SHP2, a ubiquitously expressed
protein tyrosine phosphatase, is required for the full activation
of the Ras-Erk mitogenic pathway. Through the complex forma-
tion, CagA deregulates the phosphatase activity of SHP2, which
in turn potentiates Ras-Erk signaling (Saito et al., 2010). CagA-
activated SHP2 also dephosphorylates focal adhesion kinase,
a kinase-regulating cell shape and motility, and thereby inhibits
the its kinase activity, causing impaired focal adhesions that
are associated with an elongated cell shape known as the hum-
mingbird phenotype and elevated cell motility (Segal et al., 1999;
Tsutsumi et al., 2006). The CagA-SHP2 interaction has drawn
much attention because SHP2 is a potential oncoprotein (Mato-
zaki et al., 2009). Somatic gain-of-function mutations in PTPN11,
the gene encoding SHP2, are found in a variety of human
cancers, and thus SHP2 is recognized as a proto-oncogenic
phosphatase (Chan and Feng, 2007). Remarkably, the EPIYA-
D segment binds to SHP2 more strongly than the EPIYA-C
segment does. Additionally, transgenic mice expressing East
Asian CagA develop tumorsmore frequently than those express-
ing Western CagA (Miura et al., 2009). Clinically, infection with
H. pylori carrying East Asian CagA is associated with severe
gastric atrophy and gastric cancer (Satomi et al., 2006).
Altogether, these results indicate that endemic circulation of
H. pylori carrying biologically more active CagA may be one
major factor underpinning the high incidence of gastric cancer
in East Asian countries. In Western countries, infection with
H. pylori cagA-positive strains with larger numbers of CagA
EPIYA-C segments was associated with atrophic gastritis and
increased the risk of gastric cancer (Basso et al., 2008; Ferreira
et al., 2012). Apart from its contribution in carcinogenesis, a5, March 12, 2014 ª2014 Elsevier Inc. 307
Cell Host & Microbe
Reviewpotential role for the CagA-SHP2 interaction in bacterial coloni-
zation has also been described. During infection with cagA-pos-
itiveH. pylori, CagA-deregulated SHP2 inhibits the expression of
b-defensin 3, an antimicrobial peptide active againstH. pylori, by
tyrosine-dephosphorylating EGF receptor and thereby terminat-
ing EGF-dependent intracellular signaling events (Bauer et al.,
2012). Along with the report that CagA induces REG3g, a
secreted C-type lectin that exerts direct bactericidal activity
(Lee et al., 2012), CagA deliverymay allowH. pylori tomanipulate
host innate immunity in order to favor its own survival in the
stomach mucosa.
The tyrosine-phosphorylated EPIYA-A or EPIYA-B segment
also binds to the SH2 domain of the protein tyrosine kinase
Csk (Hatakeyama, 2004). The CagA-Csk interaction recruits
Csk to the plasma membrane, where Csk phosphorylates
membrane-bound SFKs. Given that phosphorylation inhibits
SFK kinase activity, Csk activation results in reduced EPIYA
phosphorylation of CagA. Therefore, the CagA-Csk interaction
may establish a negative feedback regulatory loop that prevents
excess activation of tyrosine phosphorylation-dependent CagA
activity, which could be harmful to the long-term colonization
of H. pylori in the stomach. Inhibition of SFK activity by CagA
also alters the phosphorylation status of actin binding proteins
such as cortactin and vinculin, resulting in actin cytoskeletal re-
arrangements that promote cell motility (Tegtmeyer and Backert,
2011).
In addition to SHP2 and Csk, CagA associates with Crk
adaptor proteins (Crk-I, Crk-II, and Crk-L) in an EPIYA-phos-
phorylation-dependent manner (Suzuki et al., 2005), although
details of these interactions are unknown. The resulting CagA-
Crk complex exerts pleiotropic effects on signaling pathways,
such as Sos1/H-Ras/Raf1, C3G/Rap1/B-Raf, and Dock180/
Rac1/WASP, that control cell spreading, motility, and prolifer-
ation and thus further enhance the motogenetic activity of
CagA. Systemic proteomic screening with high resolution
mass-spectrometry revealed that EPIYA-containing peptides
derived from CagA are capable of interacting with a variety of
SH2-containing proteins in a tyrosine-phosphorylation-depen-
dent manner (Selbach et al., 2009), suggesting that SH2 domain
selectivity of the bacterial EPIYA segments is unexpectedly low.
CagA has also been reported to interact with the adaptor protein
Grb2 and thereby activates Ras-Erk signaling in an EPIYA-
dependent manner (Mimuro et al., 2002). However, the
CagA-Grb2 interaction occurs independently of EPIYA tyrosine
phosphorylation, arguing against the idea that the interaction in-
volves the SH2 domains of Grb2. Altogether, the bacterial
protein targets pro-oncogenic Ras signaling through multiple
distinct mechanisms.
Given that recently identified bacterial tyrosine kinases (BY ki-
nases) share no homology with eukaryotic tyrosine kinases (Lee
and Jia, 2009) and that there is no evidence indicating that
CagA is tyrosine phosphorylated inside the bacteria, the origin
of the EPIYA tyrosine-phosphorylation motif in CagA remains
enigmatic. In mammalian proteomes, EPIYA- or EPIYA-like-
motif-containing proteins have been reportedly underrepre-
sented (Selbach et al., 2009), whereas several bacterial effectors
other thanCagA also contain EPIYA or EPIYA-likemotifs that can
undergo tyrosine phosphorylation upon delivery into mammalian
cells (Hayashi et al., 2013). Along with the seemingly low SH2308 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.domain selectivity, these findings led to the proposal of a ‘‘mas-
ter key’’ hypothesis that bacterial EPIYA effectors promiscuously
perturb a variety of mammalian SH2-containing proteins, activity
that may be dangerous for the sophisticated regulation of
the SH2-domain-mediated signaling network in mammalian
cells (Selbach et al., 2009). This interesting possibility obviously
warrants further investigation.
Be that as it may, there exists a mammalian protein (termed
Pragmin or Sgk223) that undergoes tyrosine phosphorylation
on the EPIYA motif by SFKs (Safari et al., 2011). Pragmin was
originally identified as a cytoplasmic pseudokinase that specif-
ically stimulates RhoA GTPase activity upon interacting with
Rnd2 GTPase (Tanaka et al., 2006). In stark contrast to the
unfaithful bacterial EPIYAmotif, the Pragmin EPIYA motif specif-
ically binds to the SH2 domain of Csk, and, unlike the CagA-Csk
interaction, the Pragmin-Csk interaction sequesters Csk in the
cytoplasm, thereby preventing Csk-mediated SFK phosphoryla-
tion and inactivation at the membrane. Thus, Pragmin negatively
regulates the Csk-SFK signaling axis in an EPIYA-dependent
manner, giving rise to sustained activation of SFKs. Since
many bacterial EPIYA effectors commonly target Csk (Hayashi
et al., 2013), it is possible that the Csk-SFK axis is an Achilles’
heel overlooked in mammalian cells, the malfunction of which
may greatly increase the chance of successful bacterial infec-
tion.
CM-Motif-Mediated CagA-Host Protein Interactions
The CagA C-terminal region also contains a 16-amino-acid
sequence termed the CagA-multimerization (CM) motif, the
number of which varies among distinct CagA species (Figure 1)
(Ren et al., 2006). East Asian CagA contains a single CM motif
(termed East Asian CM) that is located immediately distal to
the EPIYA-D segment. Western CagA also has a CM motif after
the last repeat of the EPIYA-C segment, which is either the same
as East Asian CM or closely related to it (termed Western CM).
Interestingly, the N-terminal 16-amino-acid residues of the
EPIYA-C segment are completely identical to those of Western
CM. Thus, almost all Western CagA species contain two or
more CM motifs (Hatakeyama, 2011). Although the CM motif
was originally identified as a sequence that directs CagA dimer-
ization, it acts as a binding site for a polarity-regulating serine/
threonine kinase, partitioning defective-1 (PAR1; also known
as microtubule affinity-regulating kinase in mammals). Through
complex formation, the CMmotif occupies the substrate binding
cleft of PAR1 and thereby inhibits its kinase activity (Saadat et al.,
2007; Nesic et al., 2010). Of four PAR1 isoforms (PAR1a–PAR1d)
in mammals, CagA binds most strongly to PAR1b, a predomi-
nant PAR1 member in epithelial cells (Hatakeyama, 2011).
Because PAR1b forms a homodimer in the cell (Nagase et al.,
2011), the resulting PAR1b dimer is capable of interacting with
two CagA molecules simultaneously. This was the reason why
the PAR1 binding sequence was originally defined as the motif
through which CagA multimerizes (dimerizes). The ‘‘passive’’
dimerization of CagA is important for the increased biological
activity of CagA carrying a single EPIYA-C or EPIYA-D segment,
whereas monovalent interaction of such a type of CagA with one
of the two SH2 domains of SHP2 is relatively weak, PAR1-medi-
ated CagA dimerization enables divalent interaction of the two
SH2 domains of a single SHP2 with two CagA proteins in trans,
Figure 2. Coordinated Deregulation of Ras and Wnt Pathways by
CagA
Membrane-tethered CagA recruits a fraction of cytoplasmic SHP2 to the
membrane. CagA-deregulated SHP2 hyperstimulates Ras-Erk signaling.
Activated Ras, while inducing a mitogenic signal, promotes nuclear trans-
localization of cytoplasmic SHP2, which is not bound to CagA. At the mem-
brane, CagA also dissociates b-catenin from E-cadherin and accelerates its
nuclear translocalization. In the nucleus, where both SHP2 and b-catenin are
forced to accumulate by the action of CagA, SHP2 dephosphorylates parafi-
bromin (PF) and thereby enables the formation of the PF/b-catenin complex,
which potentiates the activation of Wnt target genes.
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plex (Nagase et al., 2011). Meanwhile, a CagA protein possess-
ing more than two EPIYA-C segments can stably associate with
a single SHP2 in cis, and the amount of the CagA-SHP2 complex
exponentially increases as the repeat number of EPIYA-C seg-
ments in a single CagA protein increases.
PAR1 is required for the development and maintenance of
tight junctions (Suzuki and Ohno, 2006). Therefore, the inhibition
of PAR1 activity by CagA leads to the disruption of tight junctions
(Saadat et al., 2007). Given that tight junctions not only act as an
intercellular barrier but also determine the apical and lateral
membrane border, their disruption also causes a loss of epithe-
lial apical-basal polarity. As a consequence, CagA-expressing
cells extrude from the surrounding polarized epithelial monolayer
and initiate multiple rounds of cell divisions, whereas undergoing
morphological changes resembling the epithelial-mesenchymal
transition (EMT) (Bagnoli et al., 2005; Saito et al., 2010). PAR1
also regulates the stability of microtubules by phosphorylating
microtubule-associated proteins (Timm et al., 2008). Because
the mitotic spindle is a microtubule-based structure, impaired
functioning of microtubules by CagA-mediated PAR1 inhibition
also perturbs mitosis, especially the segregation of sister chro-
matids (Umeda et al., 2009). Thus, CagA-expressing cells
display chromosomal instability (CIN), a phenotype that plays
an important role in the neoplastic transformation of cells. While
promoting epithelial carcinogenesis, the CagA-PAR1 interaction
has a unique role in the establishment of H. pylori infection. In a
polarized epithelial monolayer, cagA-positive H. pylori is able to
replicate and grow directly on the cell surface. This infection pro-
cess requires the disruption of epithelial cell polarity, which en-
ables adhered H. pylori to convert the apical membrane into areplicative niche via CagA-mediated PAR1 inhibition (Tan et al.,
2009). Although the precise mechanisms remain unknown,
CagA-mediated polarity loss also stimulates the mislocalization
of transferrin receptor apically to sites of bacterial microcolonies,
ensuring the acquisition of iron from the host cell for bacterial
growth and proliferation (Tan et al., 2011).
CagA interacts with E-cadherin independently of tyrosine
phosphorylation (Murata-Kamiya et al., 2007). Given that the
interaction requires the CMmotif, CagAmay indirectly associate
with E-cadherin via PAR1. The CagA-E-cadherin interaction de-
stabilizes the E-cadherin/b-catenin complex to release b-catenin
to the cytoplasm and/or nucleus. b-catenin is a key target of the
canonical Wnt signaling pathway that plays critical roles in em-
bryonic development and tissue homeostasis. In the canonical
Wnt signaling pathway, binding of Wnt ligands to the Frizzled re-
ceptors leads to the stabilization of b-catenin, which then enters
the nucleus and transactivates Wnt target genes. Consistent
with the notion that Wnt target genes are critically involved in
the regulation of cell proliferation and differentiation, deregulated
b-catenin is associated with various human cancers (Saito-Diaz
et al., 2013). It was recently reported that activated Ras-Erk
signaling enhances nuclear translocalization of cytoplasmic
SHP2 that is bound to YAP or its homolog TAZ, a target of the
tumor-suppressive Hippo signaling pathway that controls cell
proliferation and apoptosis (Takahashi et al., 2011; Tsutsumi
et al., 2013). In the nucleus, SHP2 mediates tyrosine dephos-
phorylation of parafibromin (also known as CDC73), enabling
complex formation of parafibromin with b-catenin, which en-
hances Wnt target gene activation. Altogether, membrane-teth-
ered CagA recruits a fraction of cytoplasmic SHP2 molecules to
the membrane, where SHP2 potentiates the Ras-Erk signaling,
which in turn promotes nuclear translocalization of CagA-un-
bound SHP2. Accordingly, in cells expressing CagA, both b-cat-
enin and SHP2 are forced to accumulate in the nucleus, where
they collaborate in aberrant Wnt activation (Figure 2). In addition
to PAR1, CagA associates with the c-Met receptor tyrosine ki-
nase through the CMmotif. The interaction deregulates c-Met ki-
nase activity and thus aberrantly stimulates PI3-kinase/Akt
signaling, which further potentiates Wnt signaling by preventing
b-catenin degradation (Suzuki et al., 2009). Transgenic expres-
sion of CagA in the intestinal tract of Zebrafish resulted in
abnormal proliferation of epithelial cells via Wnt activation,
providing in vivo evidence for the pathophysiological interaction
between CagA and the Wnt pathway (Neal et al., 2013). The
importance of b-catenin activation in gastric carcinogenesis is
also supported by the observation that malignant lesions in the
stomach of Mongolian gerbils infected with a carcinogenic
H. pylori strain are characterized by the nuclear accumulation
of b-catenin and activation of Wnt target genes (Franco et al.,
2005). Considering the role of the CM motif in the interaction of
CagA with cellular targets such as PAR1 and c-Met, variations
in its number and sequence may also influence the degree of
CagA virulence and disease outcome as with the cases of
CagA EPIYA segments.
Tertiary Structural Basis of CagA Action
3D structural analysis of CagA revealed that the bacterial
oncoprotein has a unique tertiary structure consisting of a solid
N-terminal region (70% of the entire CagA) and an intrinsicallyCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 309
Figure 3. Flip-Flop Regulation of CagA
Activity
CagA is delivered into gastric epithelial cells via the
H. pylori type IV secretion system, where it acts as
an oncogenic scaffold or hub. The CagA protein
consists of structured N-terminal and disordered
C-terminal regions. Folded N-terminal CagA dis-
plays a heretofore unidentified structure with three
distinct domains (domains I–III). Domain I (blue)
constitutes the N terminus, whereas domain II
(yellow) tethers CagA to the inner plasma
membrane via the basic patch (green)-phospha-
tidylserine (pink) interaction. Intramolecular
interaction with domain III (red) potentiates binding
capability of the disordered C-terminal tail with
PAR1 and SHP2, thereby enhancing the onco-
genic scaffold or hub function of CagA.
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the EPIYA segments and the CMmotifs (Figure 3) (Hayashi et al.,
2012b; Kaplan-Tu¨rko¨z et al., 2012). The N-terminal core predicts
a square plate-like shape with approximate dimensions of 1103
80 3 55 A˚3 comprising three discrete domains, termed domains
I–III. Domain I, the most N-terminal domain, has a small interact-
ing surface area with domain II but not domain III. Because of
this, domain I is quite mobile and flexible. Domains II and III
comprise a protease-resistant structural CagA core. Domain II
also contains a large antiparallel b sheet, with which CagA binds
to the host membrane b1-integrin for its delivery. The disordered
C-terminal tail loops back onto domain III to form a lariat loop
that strengthens interaction with PAR1 and SHP2. Therefore,
the degree of the scaffold or hub function of CagA is fine-tuned
by the intramolecular interaction (Figure 3).
Delivered CagA is tethered to the inner face of the plasma
membrane. The mechanism underlying CagA-host membrane
interaction is rather complicated, given that it involves at least
two distinct CagA regions, the basic patch and the EPIYA motif,
in a cell-context-dependent manner (Higashi et al., 2005; Mur-
ata-Kamiya et al., 2010; Hayashi et al., 2012b). The basic patch
is a cluster of basic residues on the surface of CagA domain II,
which adheres like Velcro to phosphatidylserine (PS), an acidic
phospholipid specifically concentrated to the inner leaflet of
the plasma membrane. The EPIYA motif also contributes to the
association of CagA with the membrane independently of phos-
phorylation. The CagA-PS interaction plays a major role in the
membrane tethering of CagA in polarized epithelial cells,
whereas the EPIYAmotif is crucial for the membrane association
of CagA in nonpolarized cells.
Although the crystal structure of Gab proteins has yet to be
determined, the structural architecture of CagA displays a
remarkable similarity to the presumed structure of mammalian
scaffold or hub proteins: the N-terminal solid domain is followed
by a long, disordered C-terminal tail, which interacts with its
target proteins in a tyrosine phosphorylation-dependent manner
(Simister and Feller, 2012). The particular structural arrangement310 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.may be a common topological architec-
ture acting as a signal integration plat-
form. Another surprising coincidence
between CagA and Gab is that the dis-
ordered C-terminal tail can interactintramolecularly with the structured N-terminal region. This
intramolecular interaction observed in CagA, which acts as a
fine tuner of the protein function, could also apply to the func-
tional regulation of mammalian scaffold or hub proteins.
The structural diversity in the C-terminal tail of CagA may well
be explained by the intrinsically disordered nature of the EPIYA
segments, which can be arranged in variable numbers and
orders through homologous recombination because there are
minimal structural constraints that restrict the combinatorial
diversification at the protein level. As proposed recently (Hayashi
et al., 2013), theduplication and/or depletionof genetic segments
encoding such disordered regions may drive rapid evolution of
bacterial EPIYA effectors both quantitatively and qualitatively.
Recent studies have shown that the structured N-terminal
CagA interacts with tumor suppressors. Interaction of N-terminal
CagA with RUNX3 induces the ubiquitination and degradation of
RUNX3 that abolishes its ability to function as a tumor suppres-
sive transcription factor (Tsang et al., 2010). N-terminal CagA
also associates with another tumor suppressor, the apoptosis-
stimulating protein of p53-2 (ASPP2). In response to DNA dam-
age, ASPP2 binds and activates p53 in order to induce
apoptosis. However, CagA promotes the proteasomal degrada-
tion of p53 by forming a CagA-ASPP2-p53 heterotrimeric com-
plex, thereby inhibiting p53-mediated apoptosis (Buti et al.,
2011). Thus, in the host cells to which it is delivered, the struc-
tured N-terminal CagA primarily acts to subvert tumor suppres-
sors, whereas the disordered C-terminal tail serves to deregulate
pro-oncogenic signaling.
CagA-Mediated Cell Reprogramming
Pathological transdifferentiation of cells increases cellular sensi-
tivity to oncogenic insults. Intestinal metaplasia of the stomach,
which is associated with long-term H. pylori infection, is thought
to be a precancerous change of the gastric mucosa (Correa,
1988). Upon ectopic expression in gastric epithelial cells, CagA
deregulates Wnt signaling and thereby aberrantly induces
Wnt targets, including CDX1, a master transcription factor
Cell Host & Microbe
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miya et al., 2007). Then, ectopically expressed CDX1 transacti-
vates stemness-associated reprogramming factors SALL4 and
KLF5 that are involved in the conversion of the CagA-expressing
gastric cells into LGR5-positive intestinal stem-like cells, which
can transdifferentiate into those with various intestinal traits (Fujii
et al., 2012). Because CDX1 binds to its own gene promoter and
generates a positive feedback loop for its own expression, once
established, the CDX1-SALL4/KLF5 transcriptional network no
longer requires CagA. This may explain sustained intestinal
metaplasia even long after eradication ofH. pylori from the stom-
ach. Considering the key biological properties shared by tissue
stem cells and cancer stem cells (Mani et al., 2008), cells en-
forced to dedifferentiate by CagA may have acquired cancer
stem-cell-like traits, making them excellent candidates from
which gastric cancer arises. Such differentiation plasticity also
suggests that the cognate gastric stem cell is not necessarily
the obligate target of CagA in terms of neoplastic transformation.
The EMT-like change induced by the expression of CagA in
polarized epithelial cells may also reflect cell reprogramming
(Amieva et al., 2003; Saito et al., 2010). Those CagA-expressing
cells display a fibroblast-like morphology, exhibiting elevated
motility, with upregulated expression of mesenchymal markers
such as ZEB1 and Snail (Bagnoli et al., 2005, Saito et al.,
2010). They also exhibit high levels of the CD44 gastric cancer
stem cell marker (Besse`de et al., 2013), reinforcing the reprog-
ramming potential of CagA. Delivered CagA undergoes auto-
phagy-dependent degradation, which is triggered by reactive
oxygen species (ROS). However, CagA can escape from the
ROS-induced autophagy in gastric cancer stem cells expressing
a variant 9 form of CD44 (CD44v9) because the variant CD44 in-
creases the level of intracellular glutathione that neutralizes ROS.
Consequently, the oncogenic action of CagA lasts substantially
longer in CD44v9-positive cells (Tsugawa et al., 2012). There-
fore, CagAmay play a special role in generating and/or maintain-
ing gastric cancer stem cells.
Hit-and-Run Carcinogenesis by CagA
Despite its critical role in the development of gastric cancer,
established gastric cancer cells maintain their transformed
phenotypes in the absence of CagA. This leads to the idea that
CagA-mediated gastric carcinogenesis progresses through a
hit-and-run mechanism. Hit-and-run carcinogenesis was origi-
nally proposed by Skinner (1976) to explain certain types of
virus-induced cancers. The conventional concept of viral carci-
nogenesis requires the presence of virus-specific oncogenes
to maintain a malignant phenotype. In contrast, according to
the hit-and-run model, a virus can initiate cell transformation
while it (or its product) is no longer present in transformed cells.
The model has been implicated in human neoplasms such as
polyomavirus in brain tumors and hepatitis viruses in hepatocel-
lular carcinoma and has been supported by results of a number
of studies, including animal studies in which the expression of a
driver oncogene was conditionally turned on and off (Niller et al.,
2011; Furth, 2012).
CagA-mediated hit-and-run carcinogenesis postulates multi-
ple genomic and epigenetic alterations in the established cancer
cells that ensure their neoplastic phenotype independent ofCagA
(Figure 4). To do so, CagA may need to create some sort ofmechanisms that accelerate genetic and epigenetic changes in
host cells. In fact, this bacterial oncoprotein induces CIN by
inhibiting PAR1 (Umeda et al., 2009). Aberrant activation of
nuclear factor kB (NF-kB) upon infection with cagA-positive
H. pylori induces ectopic expression of activation-induced cyti-
dine deaminase (AID) in gastric epithelial cells, which confers a
nucleotide mutator phenotype (Marusawa and Chiba, 2010).
Additionally, the sustained activation of NF-kB in H. pylori-
infected stomach mucosa increases the level of DNA methyl-
transferases (DNMTs) (Huang et al., 2012), which mediate the
hypermethylation of a large number of genes, including those
involved in DNA mismatch repair, such as MLH1. Reduced
MLH1expressionmayunderliemicrosatellite instability observed
in a fraction of gastric cancer cases, which further deteriorates
genetic instability (Leung et al., 1999). Thesemutator phenotypes
induced by chronic infection with cagA-positive H. pylori should
cooperate with the direct oncogenic action of CagA in proceed-
ing hit-and-run carcinogenesis (for a more detailed review dis-
cussing the impact of pathogens on mechanisms that maintain
host genome integrity, please see the review by Weitzman and
Weitzman [2014] in this issue of Cell Host & Microbe).
Consistent with the elevated genetic instability as a back-
ground of hit-and-run carcinogenesis, mutations found in gastric
cancers are extremely divergent and have no characteristic
driver genemutations (Figure 4). Having said this, genes involved
in the Ras-Erk signaling pathway, such as FGFR2, KRAS, EGFR,
ERBB2, andMET, are amplified in amutually exclusivemanner in
approximately 40% of gastric cancer cases (Deng et al., 2012).
The absence of mutations in the PTPN11 gene encoding SHP2
in gastric cancer may be due to the presence of the CagA-
SHP2 complex, which dampens positive selection of cells
harboring mutant PTPN11. Remarkably, KRAS mutation, the
most common oncogene mutation in solid cancers, is extremely
rare in gastric cancer. This raises the possibility that quantitative
alteration, rather than qualitative change, in KRAS activity is a
favorite choice in complementing CagA-mediated deregulation
of Ras signaling. Nuclear accumulation of b-catenin is observed
in approximately 30% of gastric cancers (Clements et al., 2002).
In contrast to colorectal cancers, in which the APC tumor sup-
pressor gene is most commonly mutated, activating the muta-
tion of the CTNNB1 gene, which encodes b-catenin, is the major
mechanism that deregulates theWnt pathway in gastric cancers.
Again, in this instance, CagA-mediated Wnt deregulation could
be more preferentially taken over by CTNNB1 mutation than
APC mutation.
Germline mutation in the CDH1 gene encoding E-cadherin
causes hereditary diffuse gastric cancer, which comprises
approximately 1%–3% of all gastric cancers (Humar and Guil-
ford, 2009). In sporadic cases, CDH1 mutation is found in more
than half of diffuse-type cancers, whereas it is rare in intesti-
nal-type cancers. Promoter hypermethylation of CDH1 is also
frequently observed in diffuse-type gastric cancers (Yamashita
et al., 2011). Thus, sustained malfunctioning of E-cadherin,
which is initiated at the early stage by CagA and later by the mu-
tation or hypermethylation of CDH1, might be a molecular
precondition for the development of diffuse-type gastric cancer.
The incidence of p53 mutations in gastric cancer is estimated
to be approximately 30% on the basis of the 2008 International
Agency for Research on Cancer TP53 Database (Olivier et al.,Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 311
Figure 4. Hit-and-Run Model of CagA-Mediated Gastric Carcinogenesis
Direct pro-oncogenic actions of CagA include (1) aberrant activation of promitogenic signaling pathways, (2) disruption of cell-cell interaction and loss of cell
polarity, and (3) inactivation of tumor suppressors such as p53 and RUNX3. In conjunction with chronic inflammation, CagA also induces genetic and epigenetic
alterations in the host cells, which, in the long run, compensate pro-oncogenic actions of CagA via secondary alterations, thereby making cells independent of
CagA for neoplastic transformation. Loss-of-function mutation of the FAT tumor suppressor homolog 4 (FAT4) gene or the AT-rich interactive domain-containing
protein 1A (ARID1A) gene observed in 10% of gastric cancer genomes (Zang et al., 2012; Wu and Roberts, 2013) may additionally contribute to gastric
carcinogenesis by perturbing tumor suppressor pathways such as pRB or Hippo.
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Review2010), andG:C-to-A:T transition is themost common type of p53
mutation regardless of histological type. The mutational signa-
ture is explained by (1) dietary mutagens associated with the
metabolism of nitrogenous compounds, (2) nitric oxide, which
is produced by H. pylori infection, and (3) aberrant expression
of AID in gastric mucosa infected with cagA-positive H. pylori.
Interestingly, p53 mutations were found in more than 50% of
H. pylori-associated gastritis cases (Murakami et al., 1999).
Therefore, the relatively low incidence of p53mutations in estab-
lished gastric cancers (30%) suggests that inactivating muta-
tion of p53 is not necessarily a requisite for CagA-driven gastric
carcinogenesis. Enhanced degradation of p53 by the CagA-
ASPP2 interaction possibly compensates for p53 mutations
during the early phase of gastric carcinogenesis. In such cases,
malignant progression at the later phase may no longer require
p53 inactivation because other mutations are functionally com-
plementary.
Epigenetic Alterations that Support Hit-and-Run
Carcinogenesis
Epigenetic modifications such as DNA methylation and histone
modification influence gene expression without changing
genomic sequences. Gastric cancer displays a high frequency
of aberrant methylation, especially in CpG islands (CpG island
methylator phenotype [CIMP]) (Jang and Kim, 2011). This is at
leastpartly due tochronic inflammation ingastricmucosa infected
with H. pylori, given that prolonged NF-kB activation in the in-312 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.flamed mucosa could upregulate DNMTs (O’Gorman et al.,
2010). A large number of genes are repressed through hyper-
methylation in gastric cancer cells. These include tumor suppres-
sor genes such as p16, p14, E-cadherin, MGMT, RASSF1,
RUNX3, and DLC1. Notably, the expression of RUNX3 is lost in
about half of gastric cancers by hemizygous deletion and pro-
moter hypermethylation (Chuang and Ito, 2010). Therefore, the
RUNX3 inactivation may be attributable to CIN and CIMP pheno-
types in cells that have been exposed to CagA for a long time.
Although many genes are aberrantly hypermethylated, the
hypomethylation of certain genes such as the Notch ligand
Delta-like 1 has also been demonstrated in intestinal-type gastric
cancer and in the stomach of INS-GAS mice (mice bearing a
chimeric insulin-gastrin transgene) infected with H. pylori, which
recapitulates intestinal-type gastric carcinogenesis (Piazzi et al.,
2011). Notch signaling plays a critical role in tissue stem cell
maintenance, and its perturbation is associated with the devel-
opment of cancer. Although the mechanism underlying the hy-
pomethylation of particular genes in gastric cancer cells is
currently unknown, it is speculated that the activation of DNA de-
methylase via a protein-kinase C (PKC)-dependent pathway,
which could be stimulated by the gastric hormone gastrin, is
involved in the process (Tomita et al., 2011).
Role of Inflammation in CagA-Mediated Carcinogenesis
Much attention has recently focused on the role of inflammation
in fostering carcinogenesis. Since no obvious inflammatory
Figure 5. Directional Switching of CagA
Signaling
(A) In early life, injection of CagA into normal
gastric epithelial cells elicits oncogenic stress,
which induces premature cell senescence or
apoptosis. As a result, a reduced number of acid-
secreting cells and subsequent increase in gastric
pH provide direct merit for H. pylori colonization.
By inducing junctional and polarity defects, CagA
may also cause chronic gastritis and/or peptic
ulceration because of structural disintegration of
gastric mucosa.
(B) Chronic inflammation associated with long-
term cagA-positive H. pylori infection causes
genetic and epigenetic instability in the infected
stomach mucosa, which markedly enhances
the ability of cells to acquire resistance to onco-
genic stress by secondary adaptation. Delivery of
CagA into such abnormal cells switches the
direction of the CagA signal from senescence or
apoptosis to unconstraint proliferation, thereby
expanding cancer precursor cells in elderly
stomach mucosa.
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in cagA-transgenic mice, the oncogenic potential of CagA on its
own appears to be cell autonomous (Ohnishi et al., 2008). None-
theless, there is no doubt about the role of chronic inflammation
as an auxiliary engine of gastric carcinogenesis. NF-kB, a tran-
scription factor that dictates inflammation, is strongly activated
in response to H. pylori infection. Although its contribution to
H. pylori-induced NF-kB activation remains uncertain, CagA
can activate NF-kB throughmultiple distinct pathways, including
Ras, PI3K-AKT, and TRAF6-TAK1, in host cells to which it
has been delivered (Backert and Naumann, 2010). CagA has
also been reported to activate STAT3, another key transcrip-
tional factor that promotes inflammation. Although detailed
mechanisms remain to be elucidated, CagA has been shown
to deregulate STAT3 via the IL-6/gp130 signaling pathway
in a phosphorylation-independent manner (Lee et al., 2010).
Therefore, CagA phosphorylation status may determine its
downstream signaling pathway, either SHP2-Erk-NF-kB or IL-
6-JAK-STAT signaling, that leads to the activation of transcrip-
tion factors during the inflammatory process (Lee et al., 2010).
Then, activated NF-kB and/or STAT3 induce the production of
proinflammatory cytokines and antiapoptotic proteins that sup-
port the expansion of cancer-predisposed cells while preventing
apoptosis. The inflammatory responses also induce ROS, which
increases DNA damage and thereby accelerates the accumula-
tion of mutations. Additionally, cells in the chronic inflammatory
milieu undergo accelerated epigenetic alterations, which are
characteristic of CIMP through elevated DNMTs, as described
above.
An important question is whether ‘‘simple’’ but ‘‘prolonged’’
inflammation in the stomach mucosa is per se sufficient to
induce gastric cancer. A recent report on CLDN18-null mice
may provide some clues to this question. Claudin-18, encoded
by CLDN18, is the major Claudin component of tight junctions
in the stomach mucosa. CLDN18-null mice, although viable,
showed impaired tight junctions and developed chronic atrophic
gastritis and precancerous metaplasia (Hayashi et al., 2012a).Nonetheless, CLDN18-null mice developed neither dysplasia
nor carcinoma. The results of that study indicate that chronic
inflammation simply induced by physicochemical stimuli cannot
fully support multistep gastric carcinogenesis and suggest the
requirement of an additional factor, such as CagA, that can
act as an oncogenic driver during the process of neoplastic
transformation.
Conclusions and Perspectives
In most cases, H. pylori infection is established during childhood
by oral transmission. In contrast, the majority of gastric cancer
patients are over 50 years old. Considering that the generation
time of H. pylori is at most several days, killing the host due to
gastric cancer is not likely the intended outcome of this gastric
pathogen. Why then do virulent H. pylori strains carry CagA?
Once delivered, CagA immediately triggers an oncogenic signal.
However, normal epithelial cells that have received such
an oncogenic insult prevent neoplastic transformation by trig-
gering premature senescence or apoptosis (oncogenic stress
response) due, in many cases, to activation of the ARF/p53/
p21 or p16-pRB pathway (Sherr and Weber, 2000; Yaswen
and Campisi, 2007). Thus, CagA injection gives rise to a
decrease in the number of epithelial cells, which is concomitantly
associated with reduced acid secretion (hypochloridia).
Although H. pylori is able to survive under highly acidic condi-
tions, an elevated pH would be an obvious advantage for the
long-term colonization of H. pylori in the stomach (Figure 5A).
However, excessive loss of acid-secreting cells facilitates the
intrusion of oral or intestinal bacteria into the stomach due to
the neutralized pH. Accordingly, ‘‘inefficient’’ and ‘‘time-
consuming’’ killing of host cells by CagA injection, which causes
a local and moderate increase in pH at the site of H. pylori infec-
tion, would be a deliberate strategy that makes the stomach a
‘‘great sanctuary’’ for H. pylori. Such a change in gastric pH
also influences the composition of the gastric microbiota in addi-
tion to H. pylori that may additionally contribute to the develop-
ment of mucosal lesions (Sheh and Fox, 2013). Ironically, CagACell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 313
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long run, continuous exposure of epithelial cells to such a bacte-
rial effector that constantly exhibits pro-oncogenic activity
should greatly elevate the chance of cells to overcome the onco-
genic stress triggered by CagA through secondary adaptations.
According to this scenario, gastric cancer is a contingent
byproduct of long-term H. pylori infection that has become
evident with increased human longevity. Until modern civiliza-
tion, gastric cancer must have been quite rare, given that ancient
people mostly died at much younger ages. The great success of
H. pylori infection in humans may even suggest that H. pylori
infection poses some advantage to infected individuals (Cover
and Blaser, 2009). As long as host cells respond to CagA by trig-
gering premature senescence or apoptosis, the chance for
developing gastric cancer is low. On the other hand, failure
to trigger senescence or apoptosis may convert the cellular
response to CagA from an anti- to a pro-oncogenic direction.
In the gastric mucosa that has long been infected with cagA-
positiveH. pylori, CagA-induced genetic instability may promote
the generation of abnormal cells that are defective in cell machin-
eries that mediate premature senescence or apoptosis. Delivery
of CagA into such abnormal cells leads to its clonal expansion
(Figure 5B). The dual role of CagA, direct priming of pro-onco-
genic signaling and indirect generation of genomic instability,
ensures the progression of the multistep cellular process under-
lying neoplastic transformation. Therefore, it may be inevitable
that, with time, cancer precursor cells will acquire CagA inde-
pendence, making CagA-initiated gastric carcinogenesis an
excellent example of hit-and-run carcinogenesis.
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